Espicom Limited’s Report “The Outlook for Pharmaceuticals in Central & Eastern Europe” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/22/2011 -- The pharmaceutical market of Central & Eastern Europe is estimated at US$59.8 billion at retail prices in 2011; it is expected to reach US$94.5 billion by 2016. The market is expected to expand by a moderate CAGR of 7.7% in US dollar terms over the next few years as the region's economies recover from the global economic crisis.

Dominance of generic medicines
Generic medicines represent around half of the total CEE pharmaceutical market in value terms and almost three quarters in volume terms. Generics have retained their strong position in the region due to the demand for affordable drugs and the fact that some governments favour generics when selecting products for reimbursement, as they are usually cheaper than imported products and help to keep costs down. Although rising incomes have led to increased sales of branded products, recent financial difficulties are likely to have forced patients towards purchasing cheaper generics.

Central and Eastern Europe is home to a large number of generic companies, including Krka, Gedeon Richter, Polpharma and Zentiva, which have traditionally focused on the production of generics. Pharmstandard, Russia's leading generic company, has a small number of original drugs in its portfolio, but many companies lack the funding that is required for extensive R&D. Branded generics are particularly common in Central and Eastern Europe, especially in Russia, due to the tradition of self-medication which has encouraged companies to produce pharmaceuticals with recognisable names and the erroneous belief that pure generics are unsafe.

Different IP protection levels
Much of the pharmaceutical legislation within the region has been harmonised with that of the EU. However, the level of IP protection remains an international concern. Problems that are commonly raised include a lack of transparency in IP procedures and the lack of effective enforcement.

Health Expenditure
The countries of Central & Eastern Europe are projected to spend an estimated US$335.9 billion on healthcare in 2016, equal to 6.8% of GDP. At present, only 39.6% of spending in the region is private, but over 87.0% of this is composed of out-of-pocket payments. The area of private healthcare plans remains largely undeveloped within most markets. Slovenia, the wealthiest country per capita in the region, is the only state in which private plans have become a strong feature, representing over half of total private spending.

RUSSIA
Russia accounts for just under a third of the total Central & Eastern European pharmaceutical market, due to its population of 142 million; however, in per capita terms, Russia is also one of the smallest markets, similar to Romania. The Russian pharmaceutical market is predicted to expand at a relatively high CAGR in US dollar terms over the next few years and will continue to be driven by import growth; a heavy reliance on imports has resulted from the lack of locally-manufactured innovative pharmaceuticals. The government intends to change this through the Pharma 2020 Strategy, which aims to encourage growth in the local pharmaceutical industry for the period up to 2020. Under the plan, the government will help local producers to cover the costs of the R&D that is required to boost production of innovative pharmaceuticals. It also hopes to create new companies which will be able to attract investment, create new jobs and produce competitive, safe, good quality, affordable products that fulfil the requirements of patients and the healthcare system. If the objectives of the plan are realised, by 2020, the local industry will be responsible for 50% of drugs in circulation, 80% of which will be innovative. The Strategy will require a lot of investment which will be sourced mainly from the federal budget, but the government is also trying to encourage international pharmaceutical companies to invest. So far, companies such as AstraZeneca, Novo Nordisk and Nycomed have made plans to invest in Russia.

Buy Now: http://www.reportsnreports.com/reports/53463-the-outlook-for-pharmaceuticals-in-central-eastern-europe.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Wildwood Ventures Ltd’s Report “Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 5th edition” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/22/2011 -- This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2005 to mid 2011.

The report provides a detailed understand and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 1,000 links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal..

Key benefits

Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
• In-depth understanding of co-promotion and co-marketing deal trends since 2000
• Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
• Comprehensive access to over 1,000 actual co-promotion and co-marketing deals entered into by the world's iopharma companies
• Detailed access to actual co-promotion and co-marketing contracts entered into by the leading fifty bigpharma companies
• Insight into the terms included in a co-promotion and co-marketing agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.

Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:
• Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2000
• Analysis of co-promotion and co-marketing deal structure
• Case studies of real-life co-promotion and co-marketing deals
• Access to over 1,000 co-promotion and co-marketing deal records
• The leading co-promotion and co-marketing deals by value since 2000
• Most active co-promotion and co-marketing dealmakers since 2000
• The leading co-promotion and co-marketing partnering resources

The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available deal records for over 1,000 co-promotion and co-marketing deals.

Analyzing actual contract agreements allows assessment of the following:
• What are the precise co-promotion and co-marketing rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?

Buy Now: http://www.reportsnreports.com/reports/103462-co-promotion-and-co-marketing-agreements-in-pharma-biotech-and-d.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Dallas, TX -- (SBWIRE) -- 07/18/2011 -- GBI Research's report, "Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles and to Create Opportunities for Growth", provides in-depth analysis of unmet needs, drivers and barriers that impact the global kidney and renal diseases therapeutics market. The report analyzes the markets for kidney and renal diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope
The scope of this report includes -
• Annualized market data for the kidney and renal diseases therapeutics market from 2001 to 2010, forecast forward to 2017
• Analysis of the leading therapeutic segments.
• Analysis of the kidney and renal diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
• Market characterization of the kidney and renal diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns
• Key drivers and barriers that have a significant impact on the market
• Coverage of pipeline molecules in various phases of drug development
• Competitive benchmarking of leading companies.
• Key M&A activities, licensing agreements, that have taken place between 2008 and 2010 in the global kidney and renal diseases therapeutics market

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
• Develop key strategic initiatives by understanding the key focus areas of leading companies.
• Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Buy Now: http://www.reportsnreports.com/reports/90357-kidney-and-renal-diseases-therapeutics-market-to-2017-strong-pi.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

GBI Research’s Report “Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/13/2011 -- GBI Research, a leading business intelligence provider, has released its latest research "Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development", which provides insights into the unmet needs targeted by late stage pipeline molecules across major therapy areas. The report examines the safety, efficacy parameters of molecules in development. The report includes insights into the R&D pipeline various therapy areas and identifies potential blockbusters.

In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Research's team of experts.

Scope
• Profiles of promising late stage pipeline molecules across various therapy areas
• Analysis of safety, efficacy, mechanism of actions of major pipeline drugs targeted at major therapy areas
• Comparison of late stage drugs based on safety, efficacy, mechanism of action, unmet need targeted and stage of disease targeted

Reasons to buy
• Build effective strategies to launch their pipeline products by identifying geographies with high potential for growth.
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Buy Now: http://www.reportsnreports.com/reports/93452-comparative-analysis-of-late-stage-pipeline-molecules-in-major-in.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Generics Web’s Report “Daptomycin- Comprehensive patent search” is now available at ReportsnReports.com.

Dallas, TX -- (SBWIRE) -- 07/07/2011 -- Eliminate unnecessary risk with the industry benchmark in comprehensive patent information.

Pipeline Developer is a regularly updated, professional patent search performed by our expert team, which not only identifies relevant patents, but delivers categorisation and interpretation, all delivered by a convenient online interface.

The Pipeline Developer report covers Daptomycin

Daptomycin indications: Treatment of complicated skin structure infections (cSSI); Treatment of Staphylococcus Aureus infection of the bloodstream (bacteraemia) including right-side endocarditis; Treatment of mixed infections in combination with other antibacterial agent
Daptomycin innovator: Eli Lilly (Cubicin); Novartis (Cubicin); Cubist Pharm (Cubicin)

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.

Used by the world's leading generic pharmaceutical companies and legal teams, Pipeline Developer minimizes the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analyzed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on. And that means your staff can concentrate on how the patent landscape affects your business, rather than trying to source reliable patent information.

Buy Now: http://www.reportsnreports.com/reports/90113-daptomycin-comprehensive-patent-search.html

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

Pipeline Developer features:

• Comprehensive patent searching, covering the world's key territories
• Identifies patents covering molecule, formulation, process, use, combination and assay techniques
• Patent identification, categorisation and interpretation
• Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims
• Manual filtration of patents not relevant to generic development
• Updated on a monthly basis, including changes to patent families, statuses, and litigation
• Enables fast analysis and verification by hyper-linking to crucial patent documents and national registers

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Blog: http://www.reportsnreportsblog.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm